<DOC>
	<DOCNO>NCT02079909</DOCNO>
	<brief_summary>The primary objective evaluate efficacy T-817MA measure ADAS-cog ADCS-CGIC . The secondary objective : - To evaluate safety tolerability T-817MA measure clinical safety laboratory , physical examination , ECGs solicitation adverse event . - To evaluate efficacy T-817MA measure ADCS-ADL , FAQ , Neuropsychiatric Inventory ( NPI ) Mini-mental State Examination ( MMSE ) .</brief_summary>
	<brief_title>Efficacy Safety T-817MA Patients With Mild Moderate Alzheimer 's Disease ( US202 )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Male female ( postmenopausal surgically sterile ) Patients Mild moderate Alzheimer 's disease receiving donepezil ( Aricept® ) rivastigmine transdermal system ( Exelon® Patch ) , . Memantine ( Namenda® ) allow prescribed combination donepezil rivastigmine transdermal system . Age 55 85 inclusive Patients must live community Patients must eligible informant study partner ( caregiver ) Patients eligible informant study partner ( caregiver ) must able read understand English . Informed consent obtain patient caregiver Patients clinically significant cardiac , hepatic renal impairment Patient dementia Alzheimer 's type etc ( According protocol ) Patients take drug donepezil rivastigmine transdermal system Alzheimer 's disease , include olal rivastigmine ( Exelon® ) , galantamine ( Razadyne® )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Alzheimer 's</keyword>
</DOC>